[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-detail-279711-en":53,"doc-seo-279711-105":76},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":5,"data":54},{"doc_id":55,"user_id":56,"nickname":57,"user_avatar":58,"doc_module":9,"category_id":40,"category_name":41,"doc_title":59,"doc_description":60,"doc_content":61,"file_id":62,"file_url":63,"file_type":64,"file_size":65,"view_count":66,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":67,"language":68,"language_code":69,"site_id":70,"html_lang":69,"table_of_contents":71,"faqs":72,"seo_title":73,"seo_description":60,"update_tm":74,"read_time":75},279711,1236954509970,"Mack Lee","https://us-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Sample Letter of Medical Necessity - Expedite Review Request for ZOLGENSMA","Medical Necessity letter template requesting expedited review and authorization for ZOLGENSMA® gene therapy. The request outlines the patient’s identifiers, insurance and policy details, and includes ICD-10-CM diagnosis coding. It describes spinal muscular atrophy (SMA) progression, rationale for urgent intervention due to a narrow therapeutic window, and references evidence supporting early, presymptomatic treatment. The letter summarizes ZOLGENSMA clinical trial design and outcomes, including survival, developmental motor milestones, and ability-to-thrive assessments. Indication and safety information are referenced for completion.","Sample Letter of Medical Necessity  \n[Institution Letterhead][Today’s Date]  \n[Name of Health Insurance Company][PO Box or Street Address]  \n[City], [State] [ZIP Code]  \nRe: [Patient Name], [DOB], [Parent/Legal Guardian’s Name]  \nPolicy Number: [Policy Number]  \nGroup Number: [Group Number]  \nMedicaid Number (if applicable): [Medicaid Number]  \nICD-10-CM Code: [G12 .0 Infantile SMA type 1 (Werdnig-Hoffman); G12 .1 Other inherited SMA; G12 .8 Other SMAs and related syndromes; G12 .9 SMA, unspecified]  \nEXPEDITED REVIEW REQUEST FOR TREATMENT WITH ZOLGENSMA® (onasemnogene  \nabeparvovec-xioi) suspension for intravenous infusion  \nDear [Medical Director],  \nI am writing to request authorization for ZOLGENSMA gene therapy for my patient, [Patient name], [DOB],[patient weight], who has spinal muscular atrophy (SMA) . [Patient name] was diagnosed on [diagnosis date], based on genetic test results [and clinical symptoms] [and through newborn screening] . The most recent evaluation was on [evaluation date] . Due to the rapid progression of motor neuron loss and the narrow window for therapeutic intervention, I am requesting priority review and approval of ZOLGENSMA.1  \nSMA is a rare, devastating , genetic disease that causes progressive, irreversible motor neuron loss and consequent loss of neuromuscular innervation and muscle function.1-5 Children affected with one of the most severe types of SMA (SMA type 1 or infantile onset SMA) experience early and rapid onset of symptoms within the first six months of life. 1,3,4 The disease is characterized by severe muscle weakness, decline in respiratory, eating, and swallowing functions and failure to achieve important motor milestones, such as sitting without support, speaking, crawling, and walking.3,5 The rapid , progressive nature of the disease may result in respiratory failure and the need for permanent ventilatory support.6 If untreated, there is only an 8% event-free survival rate at the age of 20 months.5 Evidence suggests that motor neuron loss in SMA type 1 begins early in the perinatal period, indicating that early treatment is essential in modulating the rapid degeneration. Outcomes with presymptomatic SMA treatment are improved when more motor neurons are still viable.7,8 An expert panel assembled by Cure SMA recommends immediate, presymptomatic treatment of SMA in infants identified by newborn screening (NBS) with up to four copies of SMN2 to achieve maximal therapeutic benefit. 1,9 Therefore , it is critical to intervene with available therapies at the earliest possible time following diagnosis to achieve maximal benefit and , if possible, treat prior to symptom development.1  \nZOLGENSMA Clinical Trials Overview  \nZOLGENSMA is an adeno-associated virus (AAV) vector-based gene therapy indicated for the treatment of pediatric patients less than two years of age with SMA with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.10 ZOLGENSMA was not evaluated in patients with advanced SMA (eg, complete paralysis of limbs, permanent ventilator dependence) . ZOLGENSMA is for single-dose intravenous infusion. The efficacy of ZOLGENSMA in pediatric patients less than two years of age with SMA was evaluated by two clinical trials in which patients experienced onset of clinical symptoms before six months of age. In the STR1VE-US open-label , single-arm, phase III clinical trial (N=22), ZOLGENSMA was evaluated in pediatric patients with infantile-onset SMA.11 Efficacy was established on the basis of survival (defined as time from birth to either death or permanent ventilation) and achievement of developmental motor milestones, such as sitting without support.10 Efficacy was  \nPlease see Indication and Important Safety Information and click here for Full Prescribing Information, including Boxed WARNING for Serious Liver Injury and Acute Liver Failure.  \nalso supported by assessments of ventilator use, nutritional support, and scores on the Children's Hospital of Philadelphia Inf","cbCailCNV5QxT7bI","https://ap.wps.com/l/cbCailCNV5QxT7bI","pdf",293865,10,7,"English","en",105,"# Expedited Review Request\n## Patient and Insurance Information\n## Medical Rationale and Urgency\n## ZOLGENSMA Clinical Trials Overview\n## Efficacy Outcomes","[{\"question\":\"What information does the Medical Necessity letter template request from the provider and payer?\",\"answer\":\"It requests patient identifiers (name, DOB, weight), insurance details (policy and group numbers, Medicaid if applicable), and diagnosis coding (ICD-10-CM). It also includes institutional letterhead and the recipient medical director’s address block.\"},{\"question\":\"Why is expedited review requested for ZOLGENSMA?\",\"answer\":\"The letter emphasizes SMA’s rapid, progressive loss of motor neurons and the narrow window for effective intervention. It argues that earlier treatment—ideally presymptomatic when possible—can improve outcomes by preserving viable motor neurons.\"},{\"question\":\"How does the template describe ZOLGENSMA’s clinical evidence?\",\"answer\":\"It summarizes ZOLGENSMA as an AAV vector-based, single-dose IV gene therapy for pediatric SMA under two years. It references results from trials evaluating survival and motor milestones such as sitting without support, along with composite outcomes like ability to thrive.\"}]","Sample Letter of Medical Necessity - Expedite Review Request for ZOLGENSMA | PDF",1789525914,3,{"code":4,"msg":77,"data":78},"ok",{"site_id":70,"language":69,"slug":79,"title":59,"keywords":80,"description":60,"schema_data":81,"social_meta":136,"head_meta":138,"extra_data":140,"updated_unix":141},"sample-letter-of-medical-necessity-expedite-review-request-for-zolgensma","",{"@graph":82,"@context":135},[83,98,118],{"@type":84,"itemListElement":85},"BreadcrumbList",[86,90,93,95],{"item":87,"name":88,"@type":89,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":91,"name":10,"@type":89,"position":92},"https://docshare.wps.com/template/",2,{"item":94,"name":41,"@type":89,"position":75},"https://docshare.wps.com/template/letters/",{"item":96,"name":59,"@type":89,"position":97},"https://docshare.wps.com/template/sample-letter-of-medical-necessity-expedite-review-request-for-zolgensma/279711/",4,{"url":96,"name":59,"@type":99,"image":100,"author":105,"headline":59,"publisher":107,"fileFormat":110,"inLanguage":69,"description":60,"dateModified":111,"datePublished":112,"encodingFormat":110,"isAccessibleForFree":113,"interactionStatistic":114},"DigitalDocument",{"url":101,"@type":102,"width":103,"height":104},"https://docshare.wps.com/thumbnails/sample-letter-of-medical-necessity-expedite-review-request-for-zolgensma/279711.png","ImageObject",442,249,{"name":57,"@type":106},"Person",{"url":87,"name":108,"@type":109},"DocShare","Organization","application/pdf","2026-10-29","2026-09-16",true,{"@type":115,"interactionType":116,"userInteractionCount":66},"InteractionCounter",{"@type":117},"ViewAction",{"@type":119,"mainEntity":120},"FAQPage",[121,127,131],{"name":122,"@type":123,"acceptedAnswer":124},"What information does the Medical Necessity letter template request from the provider and payer?","Question",{"text":125,"@type":126},"It requests patient identifiers (name, DOB, weight), insurance details (policy and group numbers, Medicaid if applicable), and diagnosis coding (ICD-10-CM). It also includes institutional letterhead and the recipient medical director’s address block.","Answer",{"name":128,"@type":123,"acceptedAnswer":129},"Why is expedited review requested for ZOLGENSMA?",{"text":130,"@type":126},"The letter emphasizes SMA’s rapid, progressive loss of motor neurons and the narrow window for effective intervention. It argues that earlier treatment—ideally presymptomatic when possible—can improve outcomes by preserving viable motor neurons.",{"name":132,"@type":123,"acceptedAnswer":133},"How does the template describe ZOLGENSMA’s clinical evidence?",{"text":134,"@type":126},"It summarizes ZOLGENSMA as an AAV vector-based, single-dose IV gene therapy for pediatric SMA under two years. It references results from trials evaluating survival and motor milestones such as sitting without support, along with composite outcomes like ability to thrive.","https://schema.org",{"og:url":96,"og:type":137,"og:title":59,"og:site_name":108,"og:description":60},"article",{"robots":139,"canonical":96},"index,follow",{"doc_id":55,"site_id":70},1790508292]